Lane Michael, Executive Vice President at IDXX (Idexx Laboratories), has demonstrated a clear selling bias in recent years, with $5.7 million in total sales offset by $2.3 million in purchases across 31 transactions. The activity is concentrated entirely in IDXX shares, with no diversification across other companies. Three notable sales occurred on August 6, 2025, totaling $5.18 million—comprising transactions of $188,666, $1.56 million, and $3.53 million—alongside smaller option-related dispositions. These disposals dwarf the acquisition activity, which primarily consists of smaller purchases like the $120,912 transaction on February 14, 2025, and a $139,086 purchase on February 14, 2026.
The pattern suggests Michael has been reducing exposure to IDXX stock, with no buys recorded in the most recent filings. The sales in August 2025 represent the bulk of the divestment, while subsequent activity has been minimal aside from routine option exercises and awards. The absence of recent purchases contrasts with earlier years when Michael acquired shares more frequently, albeit at lower dollar volumes. This shift toward net selling could reflect portfolio rebalancing or liquidity needs, though the filings provide no explicit rationale. The transactions follow a predictable annual rhythm, often clustered around mid-February, likely tied to scheduled equity compensation events.
AI-assisted summary